Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
NCT04975256 · Mirati Therapeutics Inc. · PHASE1 · terminated · last registry update 2024-12-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.” | – | Registry record, Mirati Therapeutics Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KRAS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-16Results posted on the registry: Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2025-12-16Also stopped (terminated): Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2025-09-15Also stopped (withdrawn): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adagrasib + Adagrasib/Nivolumab (NCT05472623)
- 2025-07-25Also stopped (withdrawn): M.D. Anderson Cancer Center, MRTX849 (NCT05634525)
- 2025-07-22Results posted on the registry: Bristol-Myers Squibb, BMS-986466 + Adagrasib (NCT06024174)
- 2025-07-22Also stopped (terminated): Bristol-Myers Squibb, BMS-986466 + Adagrasib (NCT06024174)
- 2025-05-29Also stopped (terminated): Sanofi, Vociprotafib + Pembrolizumab (NCT04418661)
- 2025-05-01Results posted on the registry: Vitrac Therapeutics, LLC, VIC-1911 + sotorasib (NCT05374538)
- 2025-05-01Also stopped (terminated): Vitrac Therapeutics, LLC, VIC-1911 + sotorasib (NCT05374538)
- 2025-04-25Also stopped (terminated): Mirati Therapeutics Inc., Adagrasib + nab-Sirolimus (NCT05840510)
- 2025-04-20Results posted on the registry: Sanofi, Vociprotafib + Pembrolizumab (NCT04418661)
- 2025-03-13Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Pembrolizumab (NCT06875310)
- 2025-01-22Results posted on the registry: Mirati Therapeutics Inc., MRTX849 + Docetaxel (NCT04685135)
- 2024-12-12Also stopped (terminated): Navire Pharma Inc., a BridgeBio company, BBP-398 + sotorasib (NCT05480865)
- 2024-11-20Also stopped (withdrawn): ETOP IBCSG Partners Foundation, Sotorasib + Lenvatinib (NCT06068153)
- 2024-07-11Phase 3 first posted: Hoffmann-La Roche, Divarasib + Sotorasib (NCT06497556)
- 2024-04-19Results posted on the registry: Amgen, Sotorasib (NCT04887064)
- 2024-04-12Also stopped (withdrawn): Amgen, Sotorasib (NCT06061523)
- 2024-03-29Also stopped (withdrawn): NYU Langone Health, Sotorasib + Ladarixin (NCT05815186)
- 2024-03-22Results posted on the registry: Amgen, AMG 510 (NCT04380753)
- 2024-02-12Phase 3 first posted: Amgen, FOLFIRI Regimen + Sotorasib (NCT06252649)
- 2024-01-23Also stopped (withdrawn): M.D. Anderson Cancer Center, Durvalumab + Adagrasib (NCT05848843)
- 2024-01-19Results posted on the registry: Amgen, Omeprazole + Sotorasib (NCT05497557)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision